# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Matt O'Brien maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $95 t...
Stifel analyst Rick Wise maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $88 to $76.
Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:CNMD) with a Equal-Weight and lowers the price target from $77 to $71.
Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $106 to $97.
Conmed (NYSE:CNMD) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.91 by 7.69 pe...
Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $107 to $106.
Needham analyst Mike Matson reiterates Conmed (NYSE:CNMD) with a Buy and maintains $107 price target.